Thalidomide in the treatment of relapsed multiple myeloma

Mayo Clinic Proceedings

Volumn 75, Issue 9, 2000, Pages 897-901

  Vincent Rajkumar, S ^a   Fonseca, Rafal ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Lust, John A ^a   Witzig, Thomas E ^a   Kyle, Robert A ^a   Gertz, Morie A ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; LABELING INDEX; MALE; MULTIPLE MYELOMA; RELAPSE; STEM CELL TRANSPLANTATION; WOUND HEALING;

EID: 0033815863     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.9.897     Document Type: Article

References (27)

1. Landis SH, Murray T, Beiden S, Wingo PA. Cancer statistics, 1999. ÇA Cancer J Clin. 1999;49:8-31.
2. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298-1301.
3. Attal M, Harousseau J-L, Stoppa A-M, et al, Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N EngUMed. 1996;335:91-97.
4. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
5. Folkman J. Clinical applications of research on angiogenesis. N EngUMed. 1995;333:1757-1763.
6. Fox SB. Tumour angiogenesis and prognosis. Histopathology. 1997;30:294-301.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N EngUMed. 1991;324:l-8.
8. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999; 13:469-472.
9. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow ofchildren with acute lymphoblastic leukemia. Am J Pathol. 1997; 150:815-821.
10. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87: 503-508.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am StalAssoc. 1958;53:457-481.
12. Rajkumar SV, Leong T, Fonseca R, et al. Bone marrow angiogenesis has prognostic value in multiple myeloma: an Eastern Cooperative Oncology Group study [abstract]. Program P roc Am Soc Clin Oncol. 1999; 18:19a. Abstract 68.
13. Munshi N, Wilson CS, Penn J, et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies [abstract]. Blood. 1998;92(suppl l):98a. Abstract 400.
14. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
15. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Eng! J Med. 2000:342:364]. N Engl J Med. 1999:341:1565-1571.
16. Munshi N, Desikan R, Zangari M, et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM) [abstract]. Blood. 1999;94(suppl l):123a. Abstract 540.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sei USA. 1994;91: 4082-4085.
18. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
19. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol. 1998;26:217-221.
20. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and métastases. Anticancer Drugs. 1996;7:339-343.
21. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
22. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998; 187:1885-1892.
23. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigenstimulated human peripheral blood mononuclear cell cultures. Clin Explmmunol. 1995;99:160-167.
24. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213-221.
25. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
26. Rajkumar SV, Yoon SY, Li CY, et al. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells [abstract]. Blood. 1999;94(suppl l):303b. Abstract 4581.
27. Dankbar B, Padrö T, Mesters RM, et al. VEGF is expressed by myeloma cells and stimulates IL-6 secretion by microvascular endothelial and marrow stromal cells [abstract]. Blood. 1998; 92(suppl 1):68la. Abstract 2807.